Results 41 to 50 of about 12,153 (191)
, 2019 Background: Single nucleotide polymorphism (SNP) variants of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene have been studied as an important factor in neonatal hyperbilirubinemia (jaundice) severity.
Rinawati Rohsiswatmo (6850202) +5 more
core +1 more source
Association between uridin diphosphate glucuronosylotranserase 1A1 (UGT1A1) gene polymorphism and neonatal hyperbilirubinemia [PDF]
, 2017 OBJECTIVE: To assess the prevalence of UGT1A1*28 and UGT1A1*60 polymorphisms of UGT1A1 gene and their association with hyperbilirubinemia. STUDY DESIGN: DNA was isolated from Guthrie cards of 171 infants.
Krzysztof Preis +27 more
core +1 more source
, 2019 Background: Single nucleotide polymorphism (SNP) variants of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene have been studied as an important factor in neonatal hyperbilirubinemia (jaundice) severity.
Rinawati Rohsiswatmo (6850202) +5 more
core +1 more source
, 2021 Cabotegravir (CAB) is an integrase strand-transfer inhibitor of HIV that has proven effective for HIV treatment and prevention in a long-acting injectable formulation, typically preceded by an oral formulation lead-in phase.
Liu, Albert Y. +18 more
core +1 more source
The clinical application of
Human Genomics, 2010 Over the past decade, the number of pharmacogenetic tests has increased considerably, allowing for the development of our knowledge of their clinical application.
Marques Sara, Ikediobi Ogechi N
doaj +1 more source
Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan‐induced severe toxicity [PDF]
British Journal of Clinical Pharmacology, 2018 Severe irinotecan‐induced toxicity is associated with UGT1A1 polymorphisms. However, some patients develop side‐effects despite harbouring a normal UGT1A1 genotype. As CYP3A4 is also an irinotecan‐metabolizing enzyme, our study aimed to elucidate the influence of the CYP3A4*20 loss‐of‐function allele in the toxicity profile of these patients.
Pau Riera +7 more
openaire +3 more sources
BMC Cancer, 2020 Background Uridine diphosphate glucuronosyltransferase 1 family polypeptide A1 (UGT1A1) is a predictive biomarker for the side-effects of irinotecan chemotherapy, which reduces the volume of tumors harboring UGT1A1 polymorphisms.
Hideki Matsuoka +7 more
doaj +1 more source
, 2013 A: Correlation of belinostat glucuronide formation with UGT1A1 expression in human liver microsomes; B: Belinostat glucuronide formation by human liver microsomes according to wild-type, heterozygous and homozygous UGT1A1*28 genotypes.
Win-Lwin Thuya (277890) +16 more
core +1 more source
UGT1A1 polymorphisms and colorectal cancer susceptibility [PDF]
Gut, 2002 UDP-glucuronosyltransferase (UGT) 1A7 polymorphisms may be involved in the aetiology of colorectal cancer The contribution of the xenobiotic metabolising enzymes (XMEs) to disease susceptibility, particularly cancer, has been a focus for a great deal of research over the last two decades.1 Many of these genes are polymorphic and exhibit significant ...
openaire +2 more sources
Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir
Journal of Pharmacy and Pharmacology, 2017 AbstractObjectivesThe direct-acting protease inhibitor paritaprevir is a new pharmaco-logic option available for treatment of chronic hepatitis C (HCV). Paritaprevir is reported to inhibit human UGT 1A1, but the mechanism of inhibition and its possible clinical consequences are not established.
Novera Alam +2 more
openaire +2 more sources